Access to ziftomenib for leukemia patients with no other options
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial provides access to an experimental drug called ziftomenib for people with AML or ALL who have no other treatment options left. It may be a way to get this drug when you cannot join other clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL).
- You must be 18 years old or older.
- You must have tried all standard treatments without success, and there is no other similar treatment available for you.
- If you have newly diagnosed AML with a certain gene change (NPM1 mutation or KMT2A rearrangement), you may be considered if you cannot join other clinical trials.
- For KMT2A-rearranged AML, the drug will only be given along with other approved treatments that are being studied.
- You must not be able to join any ongoing clinical studies for this drug, such as due to distance or location.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral drug called ziftomenib for people with a type of acute myeloid leukemia (AML) that has certain genetic changes (NPM1 mutation or KMT2A rearrangement) and who are not able to receive standard chemotherapy. The goal is to see if ziftomenib can help control the leukemia.
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
This trial tests a new drug called ziftomenib in patients whose acute myeloid leukemia (AML) has come back or stopped responding to treatment and has a specific genetic change called an NPM1 mutation. The drug targets a protein called menin that may help cancer cells grow, and researchers hope it could help patients who have run out of standard treatment options.
This trial tests whether adding a new drug called ziftomenib to standard chemotherapy can help children whose leukemia has come back or not responded to treatment. It is for children with certain genetic changes in their leukemia cells.
This trial tests a new drug, ziftomenib, added to standard chemotherapy for adults with untreated acute myeloid leukemia (AML) who have specific gene changes (NPM1 mutation or KMT2A rearrangement). It aims to see if the combination works better than standard treatment alone.
Hear when a new Acute Lymphoblastic Leukemia, With KMT2A Rearrangements trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.